Basic Information
| LncRNA/CircRNA Name | CASC2 |
| Synonyms | CASC2, C10orf5 |
| Region | GRCh38_10:118046279-118210153 |
| Ensemble | ENSG00000177640 |
| Refseq | NR_026939 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | autophagy0 | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase report assay etc. |
| Sample | glioma tissues, cell lines (U251 and U87) |
| Expression Pattern | down-regulated |
| Function Description | CASC2 expression was significantly downregulated in glioma tissues and cell lines (U87 and U251) compared to adjacent normal brain tissues or normal human astrocytes. CASC2 may potentially serve as a valuable diagnostic and prognostic biomarker and a therapeutic target for glioma patients.CASC2 could be considered as an independent risk factor for poor prognosis. CASC2 overexpression remarkably suppressed glioma cell proliferation, migration, and invasion through suppressing Wnt/B-catenin signaling pathway. |
| Pubmed ID | 28744130 |
| Year | 2017 |
| Title | Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/B-catenin signaling pathway. |
External Links
| Links for CASC2 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |